{"denoms":[{"counts":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"73"},{"groupId":"BG003","value":"193"}],"units":"Participants"}],"groups":[{"description":"Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) twice weekly for 12 weeks via a Codetron unit","id":"BG000","title":"ALTENS: Phase II"},{"description":"5mg pilocarpine by mouth 3 times a day for 12 weeks","id":"BG001","title":"Pilocarpine: Phase III"},{"description":"Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) twice weekly for 12 weeks via a Codetron unit","id":"BG002","title":"ALTENS: Phase III"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"24","upperLimit":"80","value":"60"},{"groupId":"BG001","lowerLimit":"29","upperLimit":"78","value":"59"},{"groupId":"BG002","lowerLimit":"42","upperLimit":"83","value":"58"},{"groupId":"BG003","lowerLimit":"24","upperLimit":"83","value":"58"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"28"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"63"},{"groupId":"BG002","value":"62"},{"groupId":"BG003","value":"165"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Eligible patients (i.e. without protocol violation)"}